» Articles » PMID: 24379138

Higher Circulating Expression Levels of MiR-221 Associated with Poor Overall Survival in Renal Cell Carcinoma Patients

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2014 Jan 1
PMID 24379138
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms involved in renal cell carcinoma (RCC) development and progression remain unclear, and new biomarkers for early detection, follow-up of the disease and prognosis are needed in routine practice to improve the diagnostic and/or prognostic accuracy. There is increasing evidence that microRNAs (miRNAs) are involved in cancer development and progression. The up-regulation of miR-221/222 has been described in several human cancers, and during RCC development, this up-regulation can modulate the metastatic process. Our purpose was to investigate the circulating expression levels of miR-221/222 as potential biomarkers for RCC detection and their influence in patients' overall survival. The circulating miR-221/222 was studied by relative quantification in 77 plasma samples. A follow-up study was undertaken to evaluate the overall survival. We observed that RCC patients presented higher circulating expression levels of miR-221 and miR-222 than healthy individuals (2(-ΔΔCt) = 2.8, P = 0.028; 2(-ΔΔCt) = 2.2, P = 0.044, respectively). The RCC patients with metastasis at diagnosis also presented higher circulating expression levels of miR-221 than patients with no metastasis (2(-ΔΔCt) = 10.9, P = 0.001). We also observed a significantly lower overall survival in patients with higher expression levels of miR-221 (48 vs 116 months, respectively; P = 0.024). Furthermore, multivariate Cox regression analysis using the tumour, nodes and metastasis stage (TNM stage); Fuhrman nuclear grade and age (≥60 years) as covariants demonstrated a higher risk of specific death by cancer in patients who presented higher expression levels of miR-221 (hazard ratio (HR) = 10.7, 95% confidence interval 1.33-85.65, P = 0.026). The concordance (c) index showed that the definition of profiles that contain information regarding tumour characteristics associated with circulating miR-221 expression information presents an increased capacity to predict the risk of death by RCC (c index model 1, 0.800 vs model 2, 0.961). Our results, which identified the plasma miR-221/222 at variable levels during RCC development, suggest that these miRNAs may have a potential as noninvasive biomarkers of RCC development.

Citing Articles

An Evaluation of Serum miRNA in Renal Cell Carcinoma: A Systematic Review.

Cochetti G, Guadagni L, Paladini A, Russo M, La Mura R, Vitale A Cancers (Basel). 2025; 17(5).

PMID: 40075664 PMC: 11898939. DOI: 10.3390/cancers17050816.


MiR-501-3p/SPC24 axis affects cell proliferation, migration, invasion, apoptosis, and prognosis in renal cell carcinoma.

Liang A, Huang J, He X, Tang X, Xu X, Chen M Braz J Med Biol Res. 2025; 58:e13507.

PMID: 39907402 PMC: 11793156. DOI: 10.1590/1414-431X2024e13507.


MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration-Where Are We Now?.

Ferreira M, Morais M, Medeiros R, Teixeira A Pharmaceutics. 2024; 16(11).

PMID: 39598472 PMC: 11597238. DOI: 10.3390/pharmaceutics16111347.


A Model to Predict Prognosis of Renal Cell Clear Cell Carcinoma Based on 3 Angiogenesis-related Long Non-coding RNAs.

Chen G, Zhang T, Li F, Cui C, Huang Z, Gou X J Cancer. 2024; 15(11):3481-3494.

PMID: 38817877 PMC: 11134422. DOI: 10.7150/jca.94685.


Use of Droplet Digital Polymerase Chain Reaction to Identify Biomarkers for Differentiation of Benign and Malignant Renal Masses.

Hayden J, Wiggins A, Sullivan T, Kalantzakos T, Hooper K, Moinzadeh A Cancers (Basel). 2024; 16(4).

PMID: 38398177 PMC: 10886675. DOI: 10.3390/cancers16040787.


References
1.
Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R . Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012; 10:55. PMC: 3340316. DOI: 10.1186/1479-5876-10-55. View

2.
Calore F, Lovat F, Garofalo M . Non-coding RNAs and cancer. Int J Mol Sci. 2013; 14(8):17085-110. PMC: 3759953. DOI: 10.3390/ijms140817085. View

3.
Pfaffenroth E, Linehan W . Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008; 8(6):779-90. PMC: 2768039. DOI: 10.1517/14712598.8.6.779. View

4.
Sun Y, Yu S, Liu Y, Wang F, Liu Y, Xiao H . Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients. Int J Endocrinol. 2013; 2013:128735. PMC: 3639632. DOI: 10.1155/2013/128735. View

5.
Zhao A, Li G, Peoch M, Genin C, Gigante M . Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2012; 94(1):115-20. DOI: 10.1016/j.yexmp.2012.10.005. View